用于心肌炎免疫调节和氧化应激缓解的多功能纳米颗粒

IF 12.4 1区 医学 Q1 CHEMISTRY, MULTIDISCIPLINARY Journal of Controlled Release Pub Date : 2025-05-10 Epub Date: 2025-03-05 DOI:10.1016/j.jconrel.2025.113607
Zhou Ye , Manman Zhu , Shaojie Li , Fan Zhang , Yingqi Ran , Cong Liu , Xiangchang Xu , Shujiao Liu , Xiang Xie , Yingchen Wang , Lan Yao
{"title":"用于心肌炎免疫调节和氧化应激缓解的多功能纳米颗粒","authors":"Zhou Ye ,&nbsp;Manman Zhu ,&nbsp;Shaojie Li ,&nbsp;Fan Zhang ,&nbsp;Yingqi Ran ,&nbsp;Cong Liu ,&nbsp;Xiangchang Xu ,&nbsp;Shujiao Liu ,&nbsp;Xiang Xie ,&nbsp;Yingchen Wang ,&nbsp;Lan Yao","doi":"10.1016/j.jconrel.2025.113607","DOIUrl":null,"url":null,"abstract":"<div><div>Cardiac autoimmune injury and oxidative stress play critical roles in the development of myocarditis. Promising approaches for treating this condition include suppressing excessive immune responses and reducing oxidative stress in the myocardium. The programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) axis is known to regulate immune responses and prevent damage caused by T-cell overactivation, while elevated reactive oxygen species (ROS) contribute to the progression of myocarditis. In this study, we developed multifunctional nanoparticles (PMN@EDR) that overexpress PD-L1 and are loaded with edaravone (EDR). The PMN@EDR NPs were successfully synthesized and comprehensively characterized. PMN@EDR effectively targeted inflammation-stimulated CD4<sup>+</sup> T cells and damaged myocardial cells, inhibiting CD4<sup>+</sup> T-cell proliferation, activation, and the release of pro-inflammatory cytokines via the PD-1/PD-L1 pathway. Additionally, PMN@EDR further suppressed CD4<sup>+</sup> T-cell activation and alleviated HL-1 cardiomyocyte damage by releasing EDR to eliminate free radicals. For the in vivo treatment of myocarditis, compared to traditional single-target anti-inflammatory and antioxidant drugs, PMN@EDR not only reduced inflammation and the release of inflammatory mediators but also decreased ROS levels, thereby minimizing cardiomyocyte apoptosis and improving cardiac function. In conclusion, the PMN@EDR-based modulation of immune responses and oxidative stress offers a promising therapeutic strategy for myocarditis.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"381 ","pages":"Article 113607"},"PeriodicalIF":12.4000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multifunctional nanoparticles for immune regulation and oxidative stress alleviation in myocarditis\",\"authors\":\"Zhou Ye ,&nbsp;Manman Zhu ,&nbsp;Shaojie Li ,&nbsp;Fan Zhang ,&nbsp;Yingqi Ran ,&nbsp;Cong Liu ,&nbsp;Xiangchang Xu ,&nbsp;Shujiao Liu ,&nbsp;Xiang Xie ,&nbsp;Yingchen Wang ,&nbsp;Lan Yao\",\"doi\":\"10.1016/j.jconrel.2025.113607\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Cardiac autoimmune injury and oxidative stress play critical roles in the development of myocarditis. Promising approaches for treating this condition include suppressing excessive immune responses and reducing oxidative stress in the myocardium. The programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) axis is known to regulate immune responses and prevent damage caused by T-cell overactivation, while elevated reactive oxygen species (ROS) contribute to the progression of myocarditis. In this study, we developed multifunctional nanoparticles (PMN@EDR) that overexpress PD-L1 and are loaded with edaravone (EDR). The PMN@EDR NPs were successfully synthesized and comprehensively characterized. PMN@EDR effectively targeted inflammation-stimulated CD4<sup>+</sup> T cells and damaged myocardial cells, inhibiting CD4<sup>+</sup> T-cell proliferation, activation, and the release of pro-inflammatory cytokines via the PD-1/PD-L1 pathway. Additionally, PMN@EDR further suppressed CD4<sup>+</sup> T-cell activation and alleviated HL-1 cardiomyocyte damage by releasing EDR to eliminate free radicals. For the in vivo treatment of myocarditis, compared to traditional single-target anti-inflammatory and antioxidant drugs, PMN@EDR not only reduced inflammation and the release of inflammatory mediators but also decreased ROS levels, thereby minimizing cardiomyocyte apoptosis and improving cardiac function. In conclusion, the PMN@EDR-based modulation of immune responses and oxidative stress offers a promising therapeutic strategy for myocarditis.</div></div>\",\"PeriodicalId\":15450,\"journal\":{\"name\":\"Journal of Controlled Release\",\"volume\":\"381 \",\"pages\":\"Article 113607\"},\"PeriodicalIF\":12.4000,\"publicationDate\":\"2025-05-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Controlled Release\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168365925002160\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365925002160","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

摘要

心脏自身免疫损伤和氧化应激在心肌炎的发展中起关键作用。治疗这种疾病的有希望的方法包括抑制过度的免疫反应和减少心肌中的氧化应激。已知程序性细胞死亡蛋白1/程序性细胞死亡配体1 (PD-1/PD-L1)轴调节免疫反应并防止t细胞过度活化引起的损伤,而活性氧(ROS)升高有助于心肌炎的进展。在这项研究中,我们开发了多功能纳米颗粒(PMN@EDR),其过表达PD-L1并装载依达拉奉(EDR)。成功合成了PMN@EDR NPs并对其进行了全面表征。PMN@EDR有效靶向炎症刺激的CD4+ T细胞和受损心肌细胞,通过PD-1/PD-L1途径抑制CD4+ T细胞的增殖、活化和促炎细胞因子的释放。此外,PMN@EDR通过释放EDR消除自由基,进一步抑制CD4+ t细胞活化,减轻HL-1心肌细胞损伤。对于心肌炎的体内治疗,与传统的单靶点抗炎抗氧化药物相比,PMN@EDR不仅可以减少炎症和炎症介质的释放,还可以降低ROS水平,从而最大限度地减少心肌细胞凋亡,改善心功能。总之,PMN@EDR-based调节免疫反应和氧化应激为心肌炎提供了一种很有前途的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Multifunctional nanoparticles for immune regulation and oxidative stress alleviation in myocarditis
Cardiac autoimmune injury and oxidative stress play critical roles in the development of myocarditis. Promising approaches for treating this condition include suppressing excessive immune responses and reducing oxidative stress in the myocardium. The programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) axis is known to regulate immune responses and prevent damage caused by T-cell overactivation, while elevated reactive oxygen species (ROS) contribute to the progression of myocarditis. In this study, we developed multifunctional nanoparticles (PMN@EDR) that overexpress PD-L1 and are loaded with edaravone (EDR). The PMN@EDR NPs were successfully synthesized and comprehensively characterized. PMN@EDR effectively targeted inflammation-stimulated CD4+ T cells and damaged myocardial cells, inhibiting CD4+ T-cell proliferation, activation, and the release of pro-inflammatory cytokines via the PD-1/PD-L1 pathway. Additionally, PMN@EDR further suppressed CD4+ T-cell activation and alleviated HL-1 cardiomyocyte damage by releasing EDR to eliminate free radicals. For the in vivo treatment of myocarditis, compared to traditional single-target anti-inflammatory and antioxidant drugs, PMN@EDR not only reduced inflammation and the release of inflammatory mediators but also decreased ROS levels, thereby minimizing cardiomyocyte apoptosis and improving cardiac function. In conclusion, the PMN@EDR-based modulation of immune responses and oxidative stress offers a promising therapeutic strategy for myocarditis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Controlled Release
Journal of Controlled Release 医学-化学综合
CiteScore
18.50
自引率
5.60%
发文量
700
审稿时长
39 days
期刊介绍: The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System. Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.
期刊最新文献
Microalgal protein-alginate cryogels for enhanced lyoprotection, gastrointestinal stability, and controlled release of Lacticaseibacillus rhamnosus GG Dual ligand cooperation at the plasma membrane drives transport of engineered small extracellular vesicles across brain endothelial cells Nano-Zoledronate synergizing with TLR agonists potentiates adaptive immunity via improved lymphatic drainage and subcapsular sinus penetration Rapidly gelling platelet-rich plasma-loaded carboxymethyl hydroxybutyl chitosan hydrogel for colonic repair and adhesion reduction Harnessing the GSDME–GSDMD pyroptosis cascade to turn tumour cells into “high-energy bombs” via disulfidptosis for potent lung cancer immunotherapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1